Sean Maduck, President of Corcept Endocrinology at Corcept Therapeutics Incorporated (NASDAQ:CORT), filed a Form 4 on August 18, 2026, disclosing transactions in the company's common stock dated August 14, 2026.

Key Highlights

  • Option exercise: Maduck exercised a stock option to acquire 3,664 shares of common stock at an exercise price of $8.27 per share.
  • Shares sold: 3,664 shares were disposed of at a price of $114.49 per share under a 10b5-1 plan adopted December 8, 2025.
  • Direct ownership after transactions: 9,755 shares of common stock held directly, following the reported transactions.
  • Remaining options: 91,986 stock options with an exercise price of $8.27 and expiration date of February 10, 2027 remain beneficially owned directly.
  • Indirect holdings: Maduck also holds shares indirectly through multiple entities, including 5,147 shares via the Sean and Molly Maduck Living Trust, 20,570 shares via MMM 2025, LLC, 40,000 shares via SNM 2025 Grantor Retained Annuity Trust, 34,000 shares via SNM 2026 Grantor Retained Annuity Trust, and 10,000 shares via Duckhill Capital, LLC.

Sean Maduck's August 2026 Stock Transactions at Corcept Therapeutics

According to the filing, Sean Maduck, identified in the remarks as President of Corcept Endocrinology, executed two transactions on August 14, 2026. First, he exercised a stock option (transaction code M) covering 3,664 shares of common stock at a conversion or exercise price of $8.27 per share. That option was described as fully exercisable, with an expiration date of February 10, 2027. Following this exercise, Maduck's directly held common stock position stood at 13,419 shares.

On the same date, Maduck disposed of 3,664 shares (transaction code S) at a price of $114.49 per share, reducing his direct holdings to 9,755 shares. The filing notes this sale "was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction." After both transactions, 91,986 stock options with the $8.27 exercise price remain directly owned.

The filing also discloses that Maduck's direct common stock position includes shares underlying unvested restricted stock awards. Specifically, the filing notes 228 shares from a September 2, 2025 grant, 205 shares from a December 1, 2025 grant, 454 shares from a March 2, 2026 grant, and 615 shares from a June 1, 2026 grant. According to the filing, "100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements." Regarding the 10,000 shares held indirectly through Duckhill Capital, LLC, the filing states Maduck "disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."

What Was Disclosed

The filing reports a stock option exercise and same-day sale of 3,664 shares by Corcept Therapeutics officer Sean Maduck on August 14, 2026, executed under a pre-existing 10b5-1 plan, along with details of his direct and indirect beneficial ownership positions.